Biodexa Proposes Massive 1:10,000 Ordinary Share Reverse Split, New Deferred Shares, and Highly Dilutive Share Issuance Authority Amidst Going Concern Warning

summarizeSummary

Biodexa Pharmaceuticals Plc announced an upcoming Annual General Meeting to vote on a 1-for-10,000 reverse stock split of ordinary shares, the creation of a new class of deferred shares, and a highly dilutive authorization to issue new shares without pre-emption rights. The company's Annual Report also reiterates a 'material uncertainty' regarding its ability to continue as a going concern.

check_boxKey Events

• Proposed 1-for-10,000 Reverse Stock Split of Ordinary Shares

  Shareholders will vote on a proposal to consolidate every 10,000 existing ordinary shares into one new consolidated ordinary share. This aims to rationalize the capital structure, but highlights the extremely low underlying value of individual ordinary shares. The ADS ratio will be adjusted from 500,000:1 to 50:1 to maintain the current number of ADSs outstanding.

• Creation of 'E Deferred Shares'

  Immediately following the consolidation, each new consolidated ordinary share will be subdivided into one 'New Ordinary Share' and 9,999 'E deferred shares' with negligible rights and value. This further complicates the capital structure and effectively reduces the economic significance of a large portion of the share capital.

• Highly Dilutive Share Issuance Authority Sought

  The company is seeking authorization to allot new shares up to an aggregate nominal value of £25,000,000.00, with the ability to disapply pre-emption rights. Given the new ordinary share nominal value of £0.000001, this represents the potential to issue trillions of new shares, indicating an extremely high likelihood of significant future dilution for existing shareholders.

• Going Concern Warning Reiterated

  The Annual Report, whose posting is announced by this filing, explicitly states a 'material uncertainty' about the company's ability to continue as a going concern, citing a need for further financing. This underscores the urgency and dilutive nature of the proposed share issuance authority.

auto_awesomeAnalysis

Biodexa Pharmaceuticals Plc is undertaking a significant capital restructuring, including a massive 1-for-10,000 reverse stock split of its ordinary shares and the creation of a new class of 'E deferred shares' with negligible rights. While the number of American Depositary Shares (ADSs) will remain unchanged due to an adjusted ADS ratio (from 500,000:1 to 50:1), this reorganization addresses an 'exceptionally large number of ordinary shares' and administrative complexity, often a sign of a distressed capital structure. More critically, the company is seeking broad authority to issue new shares up to an aggregate nominal value of £25,000,000.00 and to do so without offering them to existing shareholders first. Given the nominal value of the new ordinary shares (£0.000001 each), this authorization allows for the issuance of trillions of new shares, representing an astronomical dilution potential for current shareholders. This comes alongside an explicit 'material uncertainty' warning in its Annual Report about its ability to continue as a going concern, highlighting an urgent need for additional financing.